210-kDa chimeric protein; the e1a2 BCR-ABL1 fusion subtype is found in about 70% of ALL patients and encodes a 190-kDa chimeric protein. 3, 5 Unique to the leukemic clone, the p210 and p190 BCR-ABL1
FG transcripts could serve as both therapeutic and prognostic targets.
Previous studies demonstrated that treatment with tyrosine kinase inhibitors such as imatinib, nilotinib, dasatinib, and bosutinib achieved high molecular responses in the majority of Ph + leukemia patients. [6] [7] [8] [9] [10] [11] The detection of minimal residual disease (MRD) in leukemia patients during treatment is an important prognostic marker for evaluating the risk of impending relapse. [12] [13] [14] [15] Consequently, it is essential to monitor the course of this disease for planning aggressive therapies, including allogeneic bone marrow transplants. 16 Currently, the most frequently employed methods for MRD assessment include multicolor flow cytometry, reverse transcription-polymerase chain reaction (RT-PCR), and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays, 17 the latter of which is considered to be the most sensitive technology and is thus widely used in clinical laboratories for BCR-ABL1 transcript quantification. [18] [19] [20] [21] [22] However, owing to difference in protocols, primers, standard materials, and the choice of control genes (CGs), wide variability exists among laboratories with respect to the detection rates of BCR-ABL1 FG transcripts determined by RT-qPCR. This variation creates difficulties in comparing results among laboratories and hinders the ability for clinicians to make appropriate decisions regarding the diagnosis and treatment of this disease. [23] [24] [25] [26] [27] [28] Thus, it is essential to harmonize BCR-ABL1 FG transcript quantification among laboratories.
Toward this end, recommendations and guidelines for unifying laboratory procedures such as sample preparation, primer/probe sequences, reaction conditions, and interpretations of results have been issued in recent years. 16, 23, 24, [29] [30] [31] In particular, efforts for the standardization of p210 BCR-ABL1 FG transcript quantification such as the definition of a "standardized baseline," 6, 32 proposal of an international scale (IS), 25 establishment of a conversion factor (CF), 33 standardization of definitions of the molecular response in CML, 34 and development of primary and secondary reference reagents [35] [36] [37] have not only contributed to improving the comparability of p210
BCR-ABL1 transcript values among laboratories but have also produced results on the IS. 33, [38] [39] [40] As an indispensable component of RT-qPCR, previous studies have demonstrated that using a universal standard such as the first internationally accepted plasmid-certified reference material (ERM-AD623) can improve the comparability of p210 BCR-ABL1 FG transcript quantification. 27, 41 However, currently, the standards widely used in local laboratories are mainly based on plasmids or complementary DNAs (cDNAs), which cannot reflect the entire RTqPCR process. Armored RNA technology is a mature technology that may be well suited for the preparation of quality-control or standard material, especially for infectious disease diagnosis. 42, 43 In this study, we aimed to prepare armored RNA-based p210 and p190 standards, containing both segments of the p210 or p190 BCR-ABL1 FG and four recommended CG transcripts (ABL1, BCR, B2M, and GUSB) with the ultimate goal to harmonize p210 and p190 BCR-ABL1 FG transcript quantification.
| MATERIAL S AND ME THODS

| Test materials
The pACYC-MS2 vector was successfully modified in our laboratory using the plasmid vector pACYCDuet-1 (p15A-type replication origin;
Novagen, Merck, Darmstadt, Germany) by inserting a sequence encoding the MS2 maturase and capsid protein at multiple cloning site 1 (MCS1) 44 . The pACYC-MS2-p210FG, pACYC-MS2-p190FG, and pACYC-MS2-CG recombinant plasmids were constructed previously in our laboratory with MCS2 of the pACYC-MS2 vector containing inserted sequences of the p210 BCR-ABL1 FG, p190 BCR-ABL1 FG, and four linked CGs: BCR, GUSB, B2M, and ABL1.
| Preparation of recombinant plasmids and corresponding armored RNAs
We first amplified the segments of the p210 BCR-ABL1 FG, p190
BCR-ABL1 FG, and CGs (BCR, GUSB, and B2M) from the pACYC-MS2-p210 FG, pACYC-MS2-p190 FG, and CG recombinant plasmids, and then linked segments of the p210 BCR-ABL1 FG or p190
BCR-ABL1 FG with segments of the CGs, respectively, using overlapping PCR with the primers listed in Table S1 . The final chimeric segments of the p210 BCR-ABL1 FG and CGs or p190 BCR-ABL1 FG and CGs were termed "p210FG-CG" and "p190FG-CG" (see Table S2 for sequences). We then constructed the pACYC-MS2-p210FG-CG and pACYC-MS2-p190FG-CG recombinant plasmids for expression of the corresponding p210FG-CG-and p190FG-CGarmored RNAs (Supplementary methods, sections 1-2; Table S3 ).
The recombinant plasmids pACYC-MS2-p210FG-CG and pACYC-MS2-p190FG-CG were extracted and sent to Sangon Biotech Co., Ltd. (Shanghai, China) for sequencing verification. The plasmids were also verified using Fse I/Pac I restriction enzymes, incubated at 37°C for 30 minutes, and subjected to RT-PCR using the primers listed in Table S3 . The p210FG-CG-and p190FG-CG-armored RNAs were verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transmission electron microscopy (TEM) (JEM-1400, Jeol, Tokyo, Japan), and RT-qPCR (Applied Biosystems, Foster City, CA, USA) using the primer/probe sets listed in Table S4 .
| Preparation of p210FG-CG and p190FG-CG standards
According to the results of a preliminary experiment, primary p210FG-CG-and p190FG-CG-armored RNA solutions were diluted 1000-fold with phosphate-buffered saline and designated as p210FG-CG and p190FG-CG standard S1, respectively. Then, 0.5 mL of p210FG-CG and p190FG-CG standard S1 solutions were divided into 2.0-mL ampoules and lyophilized as follows:
trays of ampoules were loaded onto lyophilizer shelves and placed at −80°C for 48 hours, and then lyophilized for at least 16 hours.
| Value assignments of p210FG-CG and p190FG-CG standards
Value assignments of p210FG-CG and p190FG-CG standards were carried out using digital PCR (dPCR) with the Europe Against Cancer primer/probe sets synthesized by Invitrogen Trading Co., Ltd.
(Shanghai, China; Table S4 ). 16, 45 The quantification procedure was performed using three randomly selected samples on three nonconsecutive days. Each sample was analyzed twice, and the mean of these six results was considered as the assigned values of the standards ( Figure 1A ). The detailed dPCR quantification procedure is described in Supplementary methods, section 3.
| Evaluation of the characteristics of p210FG-CG and p190FG-CG standards
In the short-term stability test, three groups of p210FG-CG and p190FG-CG standards were stored at 37°C, 25°C, and 4°C, respectively, for 3, 7, 15, or 30 days. In the long-term stability test, p210FG-CG and p190FG-CG standards were stored at −20°C for 1, (Table S4 ).
| Evaluation of the linearity of p210FG-CG and p190FG-CG standards
Using two RNA extraction methods, spin column and the TRIzol kit, four sets of 10-fold p210FG-CG and p190FG-CG standard dilutions
were assessed by RT-qPCR with the Europe Against Cancer primer/ probe sets, synthesized by Invitrogen Trading Co., Ltd (Table S4) .
F I G U R E 1 Value assignment, usage, and field trial of p210FG-CG and p190FG-CG standards. A, Values of p210FG-CG and p190FG-CG standards were assigned using digital PCR (dPCR) with heat lysis. B, p210FG-CG and p190FG-CG standards were used to generate curves for p210 and p190 BCR-ABL1 FG and CG quantification. C, p210FG-CG and p190FG-CG standards were evaluated in a field trial 
| Field trial evaluation of p210FG-CG and p190FG-CG standards
| Statistical analysis
Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Prism Software, San Diego, CA, USA). The Gaussian distribution of the p210 and p190%BCR-ABL1 values was tested for normality using F I G U R E 2 Verification of the recombinant plasmids pACYC-MS2-p210FG-CG and pACYC-MS2-p190FG-CG and the corresponding armored RNAs. A, The results of restriction enzyme digestion indicated that the targeted segment appeared at the expected position. B, The targeted segments could be amplified by RT-PCR. C, p210FG-CG-and p190FG-CG-armored RNAs were clearly observed by transmission electron microscopy (TEM), with a diameter of approximately 30 nm. D, In the SDS-PAGE diagram, the high concentration protein band appeared at 14 kDa, exactly corresponding to the molecular weight of the armored RNA based on MS2 nanoparticles. E, p210FG-CG-and p190FG-CG-armored RNAs could be detected by RT-qPCR the Shapiro-Wilk test. Regression analysis was applied to examine the linearity of the p210FG-CG and p190FG-CG standards. P values <.05 were considered statistically significant.
| RE SULTS
| Verification of recombinant plasmids and the corresponding armored RNAs
The results of restriction enzyme digestion (Figure 2A 
| Assigned values and evaluation of the characteristics of p210FG-CG and p190FG-CG standards
The assigned values of p210FG-CG and p190FG-CG S1 standards were 3.68 × 10 9 and 1.08 × 10 10 copies/mL, respectively (Table S5) .
No significant differences were found in the main characteristics of any of the p210FG-CG and p190FG-CG standards during storage at 4°C, 25°C, or 37°C for at least 30 days. There were also no differences detected among the p210FG-CG and p190FG-CG standards test samples when using local standards (Table 1) . For p210 samples, the coefficient of variation (CV%) of %BCR-ABL1 values of the samples was in the range of 58.6%-129.6% using local standards. Overall, 0 (0/9), 66.7% (6/9), and 33.3% (3/9) of the samples showed a CV% of <50.0%, 50.0%-80.0%, and >80.0%, respectively. For p190 samples, the CV% of %BCR-ABL1 values was in the range of 73.2%-194.0%
using local standards, with 0 (0/9), 44.4% (4/9), and 55.6% (5/9) of the samples showing a CV% of <50.0%, 50.0%-80.0%, and >80.0%, respectively ( Figure 6 ). The overall and partitioned CV% distribution of the results of the p210 and p190 samples also indicated that the variability among p210 sample results was lower than that among p190 sample results when using local standards.
Using the p210FG-CG standard, the CV% of %BCR-ABL1 values was in the range of 35.6%-124.9%, with equal distribution (33.3%, 3/9) of samples showing a CV% of <50.0%, 50.0%-80.0%, and >80.0%, and 44.% (4/9) of the samples had a decreased CV%.
Similarly, using the p190FG-CG standard, the CV% of %BCR-ABL1
values was in the range of 36.6%-170.6%, and 33.3% (3/9) of the samples showed CV% of <50.0%, 50.0%-80.0%, and >80.0%, respectively; 77.8% (7/9) of the samples had a decreased CV%.
These results indicated that the overall variability of the detected results decreased significantly when using the p210FG-CG or p190FG-CG standards, particularly for the p190FG-CG standard.
Further, among laboratories using the spin column method for RNA extraction, 66.7% (6/9) of the samples were detected with a CV% of <50.0%, and 11.1% (1/9) of the samples were detected with a CV% of >80.0%. Use of the p210FG-CG standard decreased the CV% for 88.9% (8/9) of the samples. When using the p190FG-CG standard, 88.9% (8/9) samples were detected with a CV% of <50.0%, and 11.1% (1/9) were detected with a CV% of >80.0%; as for p210FG-CG, 88.9% (8/9) of the samples showed a decreased CV%. By contrast, among laboratories using the TRIzol kit for RNA extraction, only 33.3% (3/9) samples were detected with a CV% of <50.0%, and 44.4% (4/9) samples were detected with a CV% of >80.0%; 33.3% (3/9) of the samples had a decreased CV% when using the p210FG-CG standard. Similarly, when using the p190FG-CG standard, 33.3% (3/9) of the samples were detected with a CV% of <50.0% and 33.3% (3/9) with a CV% of >80.0%; 77.8% (7/9) of the samples showed a decreased CV%.
Thus, compared to the TRIzol kit to extract RNA, use of the spin column method decreased the variability of the detection results for the p210 and p190 samples when using the p210FG-CG and p190FG-CG standards.
In addition, in laboratories using laboratory developed tests (LDTs), 44.4% (4/9) had a CV% of <50.0%, and 33.3% (3/9) samples had a CV% of >80.0%; 77.8% (8/9) of the samples showed a decreased CV% when using the p210FG-CG standard. When using the p190FG-CG standard, 66.7% (6/9) of the samples were F I G U R E 4 Evaluation of the characteristics of the p210FG-CG and p190FG-CG standards. A, Stability tests showed that the p210FG-CG and p190FG-CG standards were stable at 37°C, 25°C, and 4°C for at least 30 days, and were also stable at −20°C for at least 6 months. B, The homogeneity test showed that the p210FG-CG and p190FG-CG standards were homogeneous detected with a CV% of <50.0%, and 0 (0/9) were detected with a CV% of >80.0%; 88.9% (8/9) of the samples showed a decreased CV%. By contrast, in laboratories using commercial kits, 33.3% (3/9) of the samples were detected with a CV% of <50.0%, and 44.4% (4/9) were detected with a CV% of >80.0%; 44.4% (4/9) of the samples showed a decreased CV% when using the p210FG-CG standard. When using the p190FG-CG standard, 33.3% (3/9) of samples each were detected with a CV% of <50.0% and >80.0%; 55.6% (5/9) of the samples had a decreased CV%. Thus, compared with commercial kits, use of the p210FG-CG and p190FG-CG standards could clearly reduce the variability of the detected results for the p210 and p190 samples in laboratories that used LDTs.
Of note, for samples with a %BCR-ABL1 >10.0%, the CV% of the samples decreased when the p210FG-CG and p190FG-CG standards were used compared with when the local standards were used regardless of the RNA extraction method or assay type. Thus, use of the p210FG-CG and p190FG-CG standards could significantly decrease the variability of detection results, particularly for samples with %BCR-ABL1 >10.0%.
| D ISCUSS I ON
We successfully developed armored RNA-based p210FG-CG and p190FG-CG standards for quantification of the p210 and p190 Compared with plasmid-based standards, another valuable characteristic of armored RNA-based standards is that they can reflect the entire process of RT-qPCR, particularly RNA extraction.
BCR-ABL1
As the first step of RT-qPCR, RNA extraction plays an important role in BCR-ABL1 FG transcript quantification. 23, 24 Currently, two main methods are widely used for RNA extraction from leukemia cells: the TRIzol and spin column methods. However, different degrees of RNA loss occur during RNA extraction, which might affect the final %BCR-ABL1 value when using plasmidbased standards. According to White et al., 48 the armored RNA samples tested after RNA extraction showed a median 28-fold loss among laboratories using TRIzol-based extraction, whereas there was a median of 2-fold loss for those using spin columnbased extraction. Because RNA-based standards are affected by extraction to the same extent as patient samples, thus compensating for the variation in results, 23 the %BCR-ABL1 value of clinical samples calculated by armored RNA-based standards will better reflect the leukemic disease burden assessed at the RNA level.
Quantification of CG expression could be used for reporting the %BCR-ABL1 values, and can also be used for evaluating the quality of samples. 25 Numerous CGs for BCR-ABL1 quantification by F I G U R E 5 Linearity of p210FG-CG and p190FG-CG standards. Four series of 10-fold dilutions of the p210FG-CG (A) and p190FG-CG (B) standards were verified using two extraction methods, TRIzol and spin column extraction RT-qPCR are currently in use, such as the Abelson (ABL1), beta-actin (ACTB), beta-2-microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), porphobilinogen deaminase (PBGD), transcription factor IID (TBP), and 18S rRNA genes. 38, 41, 45 To increase the applicability of the p210FG-CG and p190FG-CG standards, four common CGs (ABL1, GUSB, B2M, and BCR) were chosen based on previous studies, [35] [36] [37] 41, 45, 49 and the segments of the CGs amplified for preparing the standards matched the recommended primer/ probe sets. 16, 22, 45 The field trial showed that these standards could be successfully detected by all participating laboratories, indicating compatibility with various RNA extraction methods, assay types, and instrument models. to avoid the variability generated by two independent standards. 50, 51 To better address this problem, according to the recommendation of Hughes et al, 25 we prepared the p210FG-CG and p190 FG-CG standards that contained segments of both the p210 BCR-ABL1 FG or p190 BCR-ABL1 FG and the CGs, and linked these segments together at a 1:1 ratio.
The coefficient of determination (r 2 ) of all standard curves of p210FG-CG and p190FG-CG in our participating laboratories was greater than 0.98, regardless of the RNA extraction method,
showing that both standards were significantly linear. The slopes of the standard curves of p210FG-CG and p190FG-CG in laboratories using the spin column method were between −3.0 and −4.0, thus meeting the criterion for the measurement of BCR-ABL1 transcripts. 23, 24 However, the slopes of the standard curves in laboratories using the TRIzol method were between −4.0 and −5.0.
Thus, further work is required to improve the slopes of the standard curves of p210FG-CG and p190FG-CG when using the TRIzol method. Based on our recent research, supplementing exogenous RNA to optimize the RNA extraction status of the armored RNA might offer a solution.
In the field trial, we found large variability in the quantification of p210 and p190 BCR-ABL1 FG transcripts by RT-qPCR using local standards, which decreased markedly using the p210FG-CG and p190FG-CG standards, independent of the RNA extraction method and assay type. Moreover, the variability of the detected results was significantly reduced when using spin column RNA extraction with the p210FG-CG and p190FG-CG standards compared with laboratories using TRIzol and/or commercial kits for extraction. We consider that the improved results of the standard curve when using the spin column are related to the lower variability of results when using the p210FG-CG and p190FG-CG standards. TA B L E 1 Results of p210 and p190 simulated samples by local standards in the multicenter field trial For laboratories using LDTs, the variability among results was lower when using the p210FG-CG and p190FG-CG standards compared with that calculated when using commercial kits. There are two potential reasons to explain this finding. First, the standards of LDTs were different among laboratories in many aspects, such as the assigned values, features, and levels. Second, the LDTs in this trial involved two independent steps (cDNA synthesis and PCR amplification), whereas laboratories using the commercial kits employed a one-step method.
The difference in assay type results among the laboratories using LDTs resulted in greater variability of RT-qPCR results than those using commercial kits. Thus, were it not for the high percentage of laboratories (88.5%) that used the same commercial kit, better harmonization effects might have been obtained in the trial.
It should be noted that the variability among the results obtained for the p190 samples was greater than that obtained for the p210 samples using local standards, and the percentage of the p190 samples with a decreased CV% using the p190FG-CG standard was higher than that for the p210 sample using the p210FG-CG standard. This might explain why the p190FG-CG standard decreased the variability of detected results more than the p210FG-CG standard.
In conclusion, we successfully developed armored RNA-based p210FG-CG and p190FG-CG standards for p210 and p190 BCR-ABL1 FG transcript quantification, respectively. The standards were stable, homogeneous, and can be mass-produced. The field trial showed that the p210FG-CG and p190FG-CG standards have favorable clinical applicability and dependability in China, and can decrease the variability among results obtained in p210 and p190 BCR-ABL1 FG transcript quantification, especially for laboratories using the spin column method for RNA extraction and for those using LDTs. 
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Comparison of CV% of sample results using local and the p210FG-CG or p190FG-CG standards. The samples with decreased CV% when using p210FG-CG or p190FG-CG standards are highlighted in red, percentages of interval distribution of CV% of samples and percentages of samples with decreased CV% are highlighted in green and orange, respectively. LDTs, laboratory developed tests
